Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
8Customers
3Debt Items
7Related Chains
Source-Backed Evidence Depth
Aspira Women's Health Inc. (AWHL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
6Distinct source URLs
16High confidence
0.858Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Aspira Women's Health Inc. Suppliers
Ticker
Name
Confidence
Evidence
CLEVELAND-CLINIC-FOUNDATION
CLEVELAND-CLINIC-FOUNDATION
92%
Aspira shall pay to CCF a partnering fee in the aggregate amount of $125,000
MAYO-COLLABORATIVE-SERVICES-INC-D-B-A-MAYO-CLINI
MAYO-COLLABORATIVE-SERVICES-INC-D-B-A-MAYO-CLINI
92%
Aspira Women's Health Inc. entered into a Laboratory Services Agreement with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories, effective as of December 16, 2025.
LINCOLN-PARK-CAPITAL-FUND-LLC
LINCOLN-PARK-CAPITAL-FUND-LLC
90%
the Company issued to Lincoln Park shares of Common Stock having an aggregate dollar value equal to 3.0% of the $10.0 million aggregate commitment
BRIGHAM-WOMEN-S-HOSPITAL
BRIGHAM-WOMEN-S-HOSPITAL
85%
On March 20, 2023, we entered into a licensing agreement with Harvard's Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz (the “Ovarian Cancer License Agreement”)
HARVARD-S-DANA-FARBER-CANCER-INSTITUTE
HARVARD-S-DANA-FARBER-CANCER-INSTITUTE
85%
On March 20, 2023, we entered into a licensing agreement with Harvard's Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz (the “Ovarian Cancer License Agreement”)
MEDICAL-UNIVERSITY-OF-LODZ
MEDICAL-UNIVERSITY-OF-LODZ
85%
On March 20, 2023, we entered into a licensing agreement with Harvard's Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz (the “Ovarian Cancer License Agreement”)
Aspira Women's Health Inc. Customers
Ticker
Name
Confidence
Evidence
MAYO-COLLABORATIVE-SERVICES-INC-D-B-A-MAYO-CLINI
MAYO-COLLABORATIVE-SERVICES-INC-D-B-A-MAYO-CLINI
92%
Aspira will provide certain reference laboratory testing services to Mayo, specifically the Ova1Plus (Ova1 and Overa) and OvaWatch tests, on a non-exclusive, as-requested basis for clinical purposes.
ASSOCIATED-REGIONAL-UNIVERSITY-PATHOLOGISTS
ASSOCIATED-REGIONAL-UNIVERSITY-PATHOLOGISTS
90%
The Company also engages in channel distribution partnerships by which OvaSuite is distributed via laboratory partners such as BioReference Health, LLC, Associated Regional University Pathologists ("…
BIOREFERENCE-HEALTH-LLC
BIOREFERENCE-HEALTH-LLC
90%
The Company also engages in channel distribution partnerships by which OvaSuite is distributed via laboratory partners such as BioReference Health, LLC, Associated Regional University Pathologists ("…
MAYO-CLINIC-LABORATORIES
MAYO-CLINIC-LABORATORIES
90%
The Company also engages in channel distribution partnerships by which OvaSuite is distributed via laboratory partners such as BioReference Health, LLC, Associated Regional University Pathologists ("…
Reciprocal relationship from DGX graph: Reciprocal relationship from AWHL graph: been unclear. ASU 2025-12 is effective for annual periods beginning after December 15, 2026, and interim periods withi…
been unclear. ASU 2025-12 is effective for annual periods beginning after December 15, 2026, and interim periods within those annual periods, with early adoption permitted. Entities may adopt the gui…
ASPIRA-LABS-INC
ASPIRA-LABS-INC
62%
Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2025, as filed on April 1, 2026, as supplemented by the section titled “Risk Factors” in this Quarterly Repo…
LINCOLN-PARK-CAPITAL-FUND-LLC
LINCOLN-PARK-CAPITAL-FUND-LLC
62%
) warrants to purchase 1,400,000 shares of Common Stock dated January 26, 2024 (the “January 2024 Warrants”), pursuant to which the Holder agreed to exercise in cash the warrants held at a reduced ex…
Aspira Women's Health Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AWHL-DEBT
Debt stack $1.2M
90%
Market cache reports total debt of $1.2M.
AWHL-DEBT-8008
Warrants outstanding: 366664
90%
xbrl warrant detail from xbrl 2025-12-31.
AWHL-DEBT-8009
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Aspira Women's Health Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Aspira Women's Health Inc..
Aspira Women's Health Inc. Ownership
Holder
Name
Confidence
Evidence
AWHL-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 2 tracked holders.
Aspira Women's Health Inc. Extended Supply Chain Network
